Evidence map›Paper›PMID 38411458›Full record

ArticleBrain : a journal of neurology2024

Novel insight into atogepant mechanisms of action in migraine prevention.

Agustin Melo-Carrillo, Andrew M Strassman, Ron Broide, Aubrey Adams, Brett Dabruzzo, Mitchell Brin, Rami Burstein

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Effectiveness of atogepant in migraine with and without medication overuse: Pooled real-world analysis of two independent clinical cohorts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Effects of photobiomodulation on nociceptor activity and the expression of proinflammatory cytokines after temporomandibular joint disc injury in rats.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Agustin Melo-CarrilloDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center. Boston, MA 02115, USA.
Andrew M StrassmanDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center. Boston, MA 02115, USA.
Ron BroideAllergan, an Abbvie Company, Irvine, CA 92612, USA.
Aubrey AdamsAllergan, an Abbvie Company, Irvine, CA 92612, USA.
Brett DabruzzoAllergan, an Abbvie Company, Irvine, CA 92612, USA.
Mitchell BrinAllergan, an Abbvie Company, Irvine, CA 92612, USA.
Rami BursteinDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center. Boston, MA 02115, USA.ORCID 0000-0003-3763-8916
AbbVie (United States) · USBeth Israel Deaconess Medical Center · USUniversity of California, Irvine · US

Funding

Photophobia during migraine: sensory, autonomic and emotional responses to lightR37NS079678 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BURSTEIN, RAMI · 2012 to 2018
$3.1M
Cortical Mechanisms of Headache: Beyond CSDR01NS094198 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BURSTEIN, RAMI · 2016 to 2020
$1.9M
Migraine pathophysiology: neural basis of photophobiaR01NS069847 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BURSTEIN, RAMI · 2010 to 2014
$1.9M
Allergan/AbbVieNIH HHS R37-NS079678NINDS NIH HHS R01 NS069847NINDS NIH HHS R01 NS094198NINDS NIH HHS R37 NS079678
6 · The paper itself

Abstract

Recently, we showed that while atogepant-a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist-does not fully prevent activation of meningeal nociceptors, it significantly reduces a cortical spreading depression (CSD)-induced early response probability in C fibres and late response probability in Aδ fibres. The current study investigates atogepant effect on CSD-induced activation and sensitization of high threshold (HT) and wide dynamic range (WDR) central dura-sensitive trigeminovascular neurons. In anaesthetized male rats, single-unit recordings were used to assess effects of atogepant (5 mg/kg) versus vehicle on CSD-induced activation and sensitization of HT and WDR trigeminovascular neurons. Single cell analysis of atogepant pretreatment effects on CSD-induced activation and sensitization of central trigeminovascular neurons in the spinal trigeminal nucleus revealed the ability of this small molecule CGRP receptor antagonist to prevent activation and sensitization of nearly all HT neurons (8/10 versus 1/10 activated neurons in the control versus treated groups, P = 0.005). In contrast, atogepant pretreatment effects on CSD-induced activation and sensitization of WDR neurons revealed an overall inability to prevent their activation (7/10 versus 5/10 activated neurons in the control versus treated groups, P = 0.64). Unexpectedly however, in spite of atogepant's inability to prevent activation of WDR neurons, it prevented their sensitization (as reflected their responses to mechanical stimulation of the facial receptive field before and after the CSD). Atogepant' ability to prevent activation and sensitization of HT neurons is attributed to its preferential inhibitory effects on thinly myelinated Aδ fibres. Atogepant's inability to prevent activation of WDR neurons is attributed to its lesser inhibitory effects on the unmyelinated C fibres. Molecular and physiological processes that govern neuronal activation versus sensitization can explain how reduction in CGRP-mediated slow but not glutamate-mediated fast synaptic transmission between central branches of meningeal nociceptors and nociceptive neurons in the spinal trigeminal nucleus can prevent their sensitization but not activation.

Indexed as

Calcitonin Gene-Related Peptide Receptor AntagonistsCortical Spreading DepressionMigraine DisordersRats, Sprague-DawleyAnimalsMaleNeuronsNociceptorsRatsReceptors, Calcitonin Gene-Related PeptideTrigeminal Nucleus, SpinalCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Calcitonin Gene-Related Peptidecentral sensitizationgepantsheadachemigrainepaintrigeminovascular

Identifiers

PMID38411458
PMCPMC11292906
OpenAlexW4392191473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.